The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
Open accessAbstract
BACKGROUND: Calcitonin gene-related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene-related peptide receptor antagonist that may be effective in acute migraine treatment. METHODS: In a multicenter, double-blind, phase 3 trial, we randomly assigned adults with at least a 1-year history of migraine and two to eight migraine attacks of moderate or severe intensity per month to receive rimegepant orally at a dose of 75 mg or matching placebo for the treatment of a single migraine attack. The primary end points were freedom from pain and freedom from the most bothersome symptom (other than pain) identified by the patient, both of which were assessed 2 hours after the dose of rimegepant or placebo was administered. RESULTS: A total of 1186 patients were randomly assigned to receive rimegepant (594 patients) or placebo (592 patients); of these, 537 patients in the rimegepant group and 535 patients in the placebo group could be evaluated for efficacy. The overall mean age of the patients evaluated for efficacy was 40.6 years, and 88.7% were women. In a modified intention-to-treat analysis, the percentage of patients who were pain-free 2 hours after receiving the dose was 19.6% in the rimegepant group and 12.0% in the placebo group (absolute difference, 7.6 percentage points; 95% confidence interval [CI], 3.3 to 11.9; P<0.001). The percentage of patients who were free from their most bothersome symptom 2 hours after the dose was 37.6% in the rimegepant group and 25.2% in the placebo group (absolute difference, 12.4 percentage points; 95% CI, 6.9 to 17.9; P<0.001). The most common adverse events were nausea and urinary tract infection. CONCLUSIONS: Treatment of a migraine attack with the oral calcitonin gene-related peptide receptor antagonist rimegepant resulted in a higher percentage of patients who were free of pain and free from their most bothersome symptom than placebo. (Funded by Biohaven Pharmaceuticals; ClinicalTrials.gov number, NCT03237845.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Pathophysiology of migraine: a disorder of sensory processing
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00034.2015 · Cited by 1,998
Self-citationVasoactive peptide release in the extracerebral circulation of humans during migraine headache
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990) · Annals of Neurology · doi:10.1002/ana.410280213 · Cited by 1,597
Self-citationGoadsby, P. J., & Edvinsson, L. (1993) · Annals of Neurology · doi:10.1002/ana.410330109 · Cited by 1,158
Self-citationHo, T. W., Ferrari, M. D., Dodick, D. W., Galet, V., Kost, J., Fan, X., Leibensperger, H., Froman, S., Assaid, C., Lines, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61626-8 · Cited by 531
Marcus, R., Goadsby, P. J., Dodick, D., Stock, D., Manos, G., & Fischer, T. Z. (2014) · Cephalalgia · doi:10.1177/0333102413500727 · Cited by 296
Self-citationHewitt, D. J., Aurora, S. K., Dodick, D. W., Goadsby, P. J., Ge, Y. (., Bachman, R., Taraborelli, D., Fan, X., Assaid, C., Lines, C., et al. (2011) · Cephalalgia · doi:10.1177/0333102411398399 · Cited by 263
Self-citationVoss, T., Lipton, R. B., Dodick, D. W., Dupre, N., Ge, J. Y., Bachman, R., Assaid, C., Aurora, S. K., & Michelson, D. (2016) · Cephalalgia · doi:10.1177/0333102416653233 · Cited by 247
Self-citationDiener, H.-C., Barbanti, P., Dahlöf, C., Reuter, U., Habeck, J., & Podhorna, J. (2011) · Cephalalgia · doi:10.1177/0333102410388435 · Cited by 214
Cited by
Diagnosis and management of migraine in ten steps
Eigenbrodt, A. K., Ashina, H., Khan, S., Diener, H.-C., Mitsikostas, D. D., Sinclair, A. J., Pozo-Rosich, P., Martelletti, P., Ducros, A., Lantéri-Minet, M., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00509-5 · Cited by 594
Croop, R., Goadsby, P. J., Stock, D. A., Conway, C. M., Forshaw, M., Stock, E. G., Coric, V., & Lipton, R. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31606-x · Cited by 403
Self-citationAtogepant for the Preventive Treatment of Migraine
Ailani, J., Lipton, R. B., Goadsby, P. J., Guo, H., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035908 · Cited by 312
Self-citationTargeting calcitonin gene-related peptide: a new era in migraine therapy
Charles, A., & Pozo-Rosich, P. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32504-8 · Cited by 304
Metadata
- Authors
- Lipton, R. B., Croop, R., Stock, E. G., Stock, D. A., Morris, B. A., Frost, M., Dubowchik, G. M., Conway, C. M., Coric, V., & Goadsby, P. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-11
- Volume
- 381
- Issue
- 2
- Pages
- 142-149
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2960467863
- Cited by
- 398
- References
- 18
- FWCI
- 32.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. https://app.cochat.ai/papers/10.1056/nejmoa1811090
- The paper
- Lipton, R. B., Croop, R., Stock, E. G., Stock, D. A., Morris, B. A., Frost, M., Dubowchik, G. M., Conway, C. M., Coric, V., & Goadsby, P. J. (2019). Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1811090
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
